Effects of intranasal estradiol treatment on serum lipoprotein(a) and lipids in hysterectomized women

Gynecologic and Obstetric Investigation

Volumn 57, Issue 4, 2004, Pages 191-195

  Kiran, Hakan ^a   Kiran, Gurkan ^a   Ekerbicer, Hasan C ^a   Kilinc, Metin ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Estrogen; Lipids; Lipoprotein(a); Menopause

Indexed keywords

ESTRADIOL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; HEMOCONCENTRATION; HUMAN; HYSTERECTOMY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, INTRANASAL; ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTRADIOL; FEMALE; HUMANS; HYSTERECTOMY; LIPIDS; LIPOPROTEIN(A); MIDDLE AGED; POSTMENOPAUSE; TRIGLYCERIDES;

EID: 2342559069     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076627     Document Type: Article

References (33)

1. Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromsø heart study. High-density lipoprotein and coronary heart disease: A prospective case-control study. Lancet 1977;i:965-968.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. Am J Med 1977;62:707-714.
3. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-1251.
4. Jovicic A, Ivanisevic V, Ivanovic I: Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993;98:59-65.
5. Santoro NF, Col NF, Eckman MH, Wong JB, Pauker SG, Cauley JA, Zmuda J, Crawford S, Johannes CB, Rossouw JE, Merz CN: Therapeutic controversy: Hormone replacement therapy - Where are we going? J Clin Endocrinol Metab 1999;84:1798-1812.
6. Bush TL, Barrett-Connor E: Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985;7:89-104.
7. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurse's health study. N Engl J Med 1991;325:756-762.
8. Bush TL: The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990;592:263-271.
9. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE: Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981;139:47-51.
10. de Aloysio D, Gambacciani M, Meschia M, Pansini F, Bacchi Modena A, Bolis PF, Massobrio M, Maiocchi G, Peruzzi E: The effect of menopause on blood lipid and lipoprotein levels: The Icarus Study Group. Atherosclerosis 1999;147:147-153.
11. Bush TL, Fried LP, Barrett-Connor E: Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem 1988;34:B60-B70.
12. Christiansen C: Hormone replacement therapy for the postmenopausal women. Maturitas 2001;38(suppl 1):S1-S5.
13. Haines CJ, Chung TK, Masarei JR, Tomlinson B, Lau JT: An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis 1996;119:215-222.
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
15. Rossouw JE, Anderson GL, Prentice RL, La-Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
16. Sacks FM, McPherson R, Walsh BW: Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106-1110.
17. Kim CJ, Jang HC, Cho DH, Min YK: Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-281.
18. Jones NS, Quraishi S, Mason JD: The nasal delivery of systemic drugs. Int J Clin Pract 1997;51:308-311.
19. Mattsson LA, Christiansen C, Colau JC, Palacios S, Kenemans P, Bergeron C, Chevallier O, Von Holst T, Gangar K: Clinical equivalance of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182:545-552.
20. Cummings SR, Black DM, Rubin SM: Lifetime risk of hip Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-2448.
21. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867.
22. Grodstein F, Stampfer MJ: The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
23. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
24. Jick H, Dinan B, Rothman KJ: Noncontraceptive estrogens and nonfatal myocardial infarction. JAMA 1978;239:1407-1408.
25. Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study. N Engl J Med 1985;313:1038-1043.
26. Wallentin L, Larsson-Cohn U: Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. II. Plasma lipids. Acta Endocrinol 1977;86:597-607.
27. Silfverstolpe G, Gustafson A, Samsioe G, Svanborg A: Lipid metabolic studies in oophorectomized women: Effects induced by two different estrogens on serum lipids and lipoproteins. Gynecol Obstet Invest 1980;11:161-169.
28. NIH Consensus Conference: Triglyceride, high-density lipoprotein, and coronary heart disease: NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA 1993;269:505-510.
29. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
30. Bush TL, Miller VT: Effects of pharmacologic agents used during menopause. Impact on lipids and lipoproteins; in Mishell D (ed): Menopause: Physiology and Pharmacology. Year Book Medical Publishers, Chicago, 1986,pp 187-208.
31. Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P: Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: A randomized controlled trial. Menopause 1998;5:157-162.
32. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
33. Palacios S: Pulsed estrogen therapy: Relieving climacteric symptoms, preventing postmenopausal bone loss. Climacteric 2002;5(suppl 2):32-39.